No Data
No Data
Jiangsu Bioperfectus Technologies Co.,Ltd. (688399.SH) has obtained EU CE certification for its related testing products.
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH) announced that nine of its products have recently received EU Regulation...
Health Check: How Prudently Does Jiangsu Bioperfectus Technologies (SHSE:688399) Use Debt?
Shuoshi Biotech (688399.SH): Dengue virus NS1 antigen test kit obtained medical device registration certificate
Gelonghui, May 10, 丨 Shuoshi Biotech (688399.SH) announced that the company recently received a medical device registration certificate (in vitro diagnostic reagent) issued by the State Drug Administration. The product name is a dengue virus NS1 antigen test kit (colloidal gold method); this kit is used to qualitatively detect dengue virus NS1 antigen in human serum or plasma samples. The acquisition of the “Medical Device Registration Certificate” mentioned above has enriched the company's product range, expanded the company's layout in the field of in vitro diagnosis, and continuously met diversified clinical needs. It will enhance the company's overall competitiveness and help further enhance the company's market expansion capabilities
Retail Investors in Jiangsu Bioperfectus Technologies Co., Ltd. (SHSE:688399) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 11% Last Week
Shuoshi Biotech (688399.SH): Net profit of 40.68 million yuan in the first quarter
Gelonghui, April 26 | Shuoshi Biotech (688399.SH) released its report for the first quarter of 2024. During the reporting period, it achieved revenue of 91.194 million yuan, a year-on-year decrease of 3.12%. Net profit attributable to shareholders of listed companies was RMB 40.68 million. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was $148.741 million.
Shuoshi Biotech (688399.SH) announced 2023 annual results with a net loss of 374 million yuan, which changed from profit to loss year-on-year
Shuoshi Biotech (688399.SH) disclosed its 2023 annual report. The company achieved operating income of 4 during the reporting period...
No Data